Malignant Neoplasm Clinical Trials in San Antonio, Texas

5 studies are recruiting for malignant neoplasm in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

   Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology ( Site 0151), San Antonio, Texas

   Locations

   8 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07600749 on ClinicalTrials.gov

2. A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

   Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mays Cancer Center ( Site 0039), San Antonio, Texas

   Locations

   59 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06979596 on ClinicalTrials.gov

3. Project: Every Child for Younger Patients With Cancer

   This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

   Stage

   Not phased

   Ages

   Up to 25

   Site

   Children's Hospital of San Antonio, San Antonio, Texas

   Locations

   279 in total

   Run by

   Children's Oncology Group

   See if you can join NCT02402244 on ClinicalTrials.gov

4. A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

   The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. This study will evaluate the efficacy of TSN1611 at RP2D(s) th…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   19 in total

   Run by

   Tyligand Pharmaceuticals (Suzhou) Limited

   See if you can join NCT06385925 on ClinicalTrials.gov

5. A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

   This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subje…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   4 in total

   Run by

   OncoResponse, Inc.

   See if you can join NCT06090266 on ClinicalTrials.gov